Катерина Сергеевна Гречухина
Moscow Clinical Scientific Center · 53 works · 36 citations · h-index 3
Top works
- Early biomarkers of nephrotoxicity associated with the use of anti‑VEGF drugs
- Dual HER2 blockade with pertuzumab+trastuzumab on the eve of a new era in the treatment of HER2-positive breast cancer
- Immunotherapy in combination with chemotherapy in triple-negative breast cancer - the first “target” therapy for the “target” patients’ population
- Unresectable hepatocellular carcinoma: prospects for drug therapy with lenvatinib
- NGAL and KIM-1 as early biomarkers of cisplatin-associated nephrotoxicity.
- NGAL and KIM-1 – early urinary biomarkers of nephrotoxicity mediated by cisplatin: Observational study
- Cross-sectional study of treatment approaches of luminal HER2negative metastatic breast cancer in real practice in Moscow
- Effectiveness of the combination of netupitant and palonosetron in the prevention of nausea and vomiting during anthracycline-containing chemotherapy in patients with breast cancer
- Abemacyclib is a unique representative of the class of CDK4/6 inhibitors in the treatment of HR+/HER2- metastatic breast cancer
- Role of palbociclib in the treatment of hormone receptor-positive HER2-negative metastatic breast cancer. Generalizing results of randomized trials and real clinical practice
- Clinical significance of MET alterations in non-small cell lung cancer and currently available therapies
- Urinary biomarkers of kidney injury in patients treated with anti-VEGF drugs
- Nephrotoxicity of anti-angiogenesis drugs
- ЭФФЕКТИВНОСТЬ АЛПЕЛИСИБА В УСЛОВИЯХ РАЦИОНАЛЬНОГО ПРИМЕНЕНИЯ МЕТФОРМИНА У ПАЦИЕНТОВ С ГОРМОНОЗАВИСИМЫМ м HR+/HER2-ОТРИЦАТЕЛЬНЫМ МЕТАСТАТИЧЕСКИМ РАКОМ МОЛОЧНОЙ ЖЕЛЕЗЫ С МУТАЦИЯМИ PIK3CA: РЕТРОСПЕКТИВНЫЙ АНАЛИЗ ОПЫТА НЕСКОЛЬКИХ РОССИЙСКИХ ЦЕНТРОВ
- Effect of internal subtype on the efficacy of CDK4/6 inhibitor therapy in advanced HR+/HER2breast cancer: A review
- Абемациклиб в реальной клинической практике адъювантной терапии HR+/HER2рака молочной железы высокого риска: опыт якорных центров г. Москвы
- Phase 2 study of combined therapy FOLFOX with dabrafenib and cetuximab/panitumumab as first-line treatment for patients with metastatic colorectal cancer MSS with BRAF V600E mutation.
- 328P Real-world evidence (RWE) of effectiveness and safety of TCHP regimen: INSIGHT-HER2BC trial interim results
- Clinical and laboratory signs and risk factors for nephrotoxicity, associated with antiangiogenic drugs
- Предварительные результаты нерандомизированного многоцентрового исследования II фазы комбинации FOLFOX с панитумумабом/цетуксимабом и дабрафенибом в первой линии лечения метастатического колоректального рака с мутацией в гене BRAF и MSS фенотипом